Research Spotlight: Dr. Neda Moatamed, GYN pathology

Dr. Neda Moatamed studies immune checkpoint regulator expression for selection of targeted therapy in neoplasms of the female reproductive organs and breast. She was the first to report EGFR deletions in lobular carcinomas of the breast. Dr. Moatamed is a respected mentor who always includes trainees in her projects. In 2017, the UCLA trainees gave her the inaugural Mentor award.

1. Kassardjian A, Shintaku PI, Moatamed NA. Expression of immune checkpoint regulators, cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed death-ligand 1 (PD-L1), in female breast carcinomas. PLoS One. 2018;13:e0195958. doi:10.1371/journal.pone.0195958

2. Moatamed NA, DeNicola M, Nham P, Phan RT. Rare occurrence of EGFR exon 19 deletion in invasive lobular carcinoma of the breast. Breast J. 2018;24:429-31. doi:10.1111/tbj.12968

3. Reddy OL, Shintaku PI, Moatamed NA. Programmed death-ligand 1 (PD-L1) is expressed in a significant number of the uterine cervical carcinomas. Diagn Pathol. 2017;12:45. doi:10.1186/s13000-017-0631-6

4. Woo JS, Apple SK, Sullivan PS, Rao JY, Ostrzega N, Moatamed NA. Systematic assessment of HER2/neu in gynecologic neoplasms, an institutional experience. Diagn Pathol. 2016;11:102. doi:10.1186/s13000-016-0553-8